Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Bronchitis Clear all
Terminated Phase 1Phase 2 Interventional Results available

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Fasciitis
Interventions
Glasdegib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 22, 2026, 5:59 PM EDT
Recruiting Phase 3 Interventional

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
30
States / cities
Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00328198
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions
Alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
La Jolla, California • La Verne, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Early Phase 1 Interventional Results available

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00870896
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
Tiotropium
Drug
Lead sponsor
ThomasTruncale
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 22, 2026, 5:59 PM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00106080
View directory record Official record
Conditions
Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
Interventions
Audit and Feedback
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Not applicable Interventional

Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease

NCT01633697
View directory record Official record
Conditions
COPD
Interventions
Pranayama, Education alone
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Houston, Texas • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 22, 2026, 5:59 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Itacitinib, Placebo, Methylprednisolone, Prednisone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Not applicable Interventional Results available

NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing

NCT02519621
View directory record Official record
Conditions
Partial-thickness Burn, Ulcer
Interventions
NPWT PRO without irrigation, NPWT PRO with irrigation, KCI Ulta
Device
Lead sponsor
Larry Lavery
Other
Eligibility
18 Years to 89 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Phase 4 Interventional

Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00667797
View directory record Official record
Conditions
Asthma, COPD
Interventions
levalbuterol HCl, albuterol Sulfate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • Chula Vista, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 22, 2026, 5:59 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

NCT01302587
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
25
States / cities
Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 22, 2026, 5:59 PM EDT
Terminated Phase 2 Interventional

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT06271616
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Echocardiography Test, Ibrutinib
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Phase 2 Interventional

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

NCT01435044
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Phase 2 Interventional Results available

Effect of BIBW 2948 BS in COPD

NCT00423137
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Music-based Treatments and Pain: Underlying Mechanisms and the Beneficial Effects of Music-Based Treatments

NCT05578781
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Music Therapy, Music Medicine, Control group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 22, 2026, 5:59 PM EDT
Recruiting Phase 2 Interventional

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

NCT07725939
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions
Galvokimig, Placebo
Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 80 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Columbus, Ohio • DuBois, Pennsylvania • Boerne, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Completed No phase listed Observational

Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.

NCT01174277
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Graft Versus Host Disease
Interventions
Collection of blood sample
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
7 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 22, 2026, 5:59 PM EDT
Terminated Phase 4 Interventional

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

NCT00132951
View directory record Official record
Conditions
Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
Interventions
Telithromycin, Azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 35 Years
Enrollment
2,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Sep 22, 2026, 5:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07128966
View directory record Official record
Conditions
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Interventions
Observation
Other
Lead sponsor
Joined Bio
Industry
Eligibility
18 Years to 90 Years
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2036
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Not yet recruiting Not applicable Interventional

Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease

NCT07733141
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Mindfulness Relaxation, Survey Administration
Procedure · Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Recruiting Phase 1 Interventional

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

NCT06991361
View directory record Official record
Conditions
Graft Versus Host Disease (cGvHD)
Interventions
EVE-Treg
Biological
Lead sponsor
Leslie Kean
Other
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 22, 2026, 5:59 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 22, 2026, 5:59 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
10 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 5:59 PM EDT